You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC / CE

BTK Inhibitors for CLL: Data Updates and Optimizing Patient Care

  • Authors: John M. Pagel, MD, PhD
  • CME / ABIM MOC / CE Released: 9/27/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 9/27/2022
Start Activity


Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, nurse practitioners, nurses, and others involved in the care of patients with CLL.

The goal of this activity is to improve the knowledge of hematologists/oncologists, nurses, and nurse practitioners regarding the safety and efficacy of BTK inhibitors in CLL as well as their competence in using these agents and managing adverse events (AEs).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Recent clinical trial data comparing BTK inhibitors in relapsed/refractory CLL
    • AE profiles of available BTK inhibitors in CLL
  • Have greater competence related to
    • Managing AEs associated with BTK inhibitors
    • Educating patients about possible AEs associated with BTK inhibitors
  • Demonstrate greater confidence in their ability to
    • Identify patients with CLL who are appropriate candidates for BTK inhibitors


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • John M. Pagel, MD, PhD

    Chief of Hematologic Malignancies
    Center for Blood Disorders and Stem Cell Transplantation
    Swedish Cancer Institute
    Seattle, Washington

    Disclosures

    Disclosure: John M. Pagel, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Actinium; AstraZeneca; Epizyme; Loxo; MEI Pharma
    Speaker or a member of a speakers bureau for: BeiGene; Gilead; MorphoSys

Editors

  • Megan Whitney, DMD

    Medical Education Director, Medscape, LLC 

    Disclosures

    Disclosure: Megan Whitney, DMD, has disclosed no relevant financial relationships. 

  • Tristin Abair, PhD

    Senior Medical Writer, Medscape, LLC 

    Disclosures

    Disclosure: Tristin Abair, PhD, has disclosed no relevant financial relationships.

CME Reviewer

  • Esther Nyarko, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Nurse Planner

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has disclosed no relevant financial relationships.

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

BTK Inhibitors for CLL: Data Updates and Optimizing Patient Care

Authors: John M. Pagel, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 9/27/2021

Valid for credit through: 9/27/2022

processing....

 
 
 

The following cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.

CASE 1: PATIENT HISTORY AND PRESENTATION

Olivia is a 71-year-old retired teacher who stays active helping her children and grandchildren. Her medical history includes well-controlled diabetes, mild renal insufficiency, and early osteoporosis. During a routine physical, her bloodwork showed lymphocytosis, with a white blood cell (WBC) count of 38,000/mm3. A full hematology workup showed monoclonal lambda-expressing B cells, with an immunophenotype by flow cytometry consistent with chronic lymphocytic leukemia (CLL) (Table 1). Molecular analysis showed no mutations in IGHV or TP53. Fluorescence in situ hybridization analysis shows deletion 13q (del(13q)) and no other adverse chromosomal abnormalities. She is currently asymptomatic.

Table 1. Olivia's Initial Workup

  Results
Demographics/patient information
  • 71 years old, female
  • Height: 5 ft 4 in; weight: 150 lb
  • BMI: 25.7
Personal and family medical history
  • History of diabetes, mild renal insufficiency, and early osteoporosis
  • No major surgeries
  • Current medications include glimepiride and ibandronate
  • No family history of cancer
Physical examination
  • No lymphadenopathy
  • No splenomegaly or hepatomegaly
  • BP: 130/85 mm HG; HR: 70 bpm
  • ECOG PS: 0
CrCl
  • 75 mL/min
CBC
  • WBC count: 38,000/mm3
  • Hb: 11.3 g/dL
  • Platelets: 132,000/mm3
Flow cytometry
  • Immunophenotype: CD5+, CD19+, CD23+, CD43+, CD79b+, CD200+, CD20-low
Cytogenetics/FISH
  • Del(13q)
  • No other chromosomal abnormalities identified
Molecular analysis
  • Unmutated IGHV
  • No TP53 mutations
BMI, body mass index; BP, blood pressure; bpm, beats per minute; CBC, complete blood cell count; CrCl, creatinine clearance; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; HR, heart rate; PS, performance status; WBC, white blood cell.

You sit down with Olivia and her husband to discuss her diagnosis and appropriate next steps.

  • Print